Tirzepatide (30mg)
Tirzepatide is a dual GLP-1/GIP agonist. The 30 mg vial is the most cost-effective option for long-term use at maintenance doses of 10–15 mg/week. Weekly subcutaneous administration.
Reviewed by the AllPeptides.eu Editorial Team·Last reviewed: 2026-06-16
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
⚠️ For informational/educational purposes only. Not medical advice. We do not sell any products. Self-treatment carries serious risks — consult a healthcare professional. Disclaimer
Research monograph
See the full Tirzepatide encyclopedia page with mechanism, evidence tier, related variants and research context.
How It Works
Tirzepatide simultaneously activates GLP-1 and GIP receptors, enhancing insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite. It has a half-life of ~5 days.
Quick Start
- Reconstitution: Add 3.0 mL bacteriostatic water → 10.0 mg/mL concentration.
- Typical weekly range: 2.5–15 mg once weekly.
- Storage: Lyophilized: −20 °C; reconstituted: 2–8 °C, use within 28 days.
Typical / Titration Approach (3 mL = 10.0 mg/mL)
Route: Subcutaneously | Frequency: Once weekly
| Week | Dose | Units (per injection) |
|---|---|---|
| Weeks 1–4 | 2.5 mg | 25 Units (0.25 mL) |
| Weeks 5–8 | 5 mg | 50 Units (0.50 mL) |
| Weeks 9–12 | 7.5 mg | 75 Units (0.75 mL) |
| Weeks 13–16 | 10 mg | 100 Units (1.00 mL) |
| Weeks 17+ | 15 mg | 2 × 75 Units (0.75 mL) |
Studies report administration once weekly. The high concentration (10 mg/mL) allows for smaller injection volumes, even at maximum doses.
Related compounds
Reconstitution Steps
- Withdraw 3.0 mL of bacteriostatic water.
- Inject slowly down the side of the vial; avoid foaming.
- Swirl gently until fully dissolved.
- Note the date; refrigerate at 2–8 °C.
Protocol Overview
- Objective: Glycemic control and weight loss via GLP-1/GIP.
- Schedule: Weekly injection for 12–24+ weeks.
- Advantage: Smaller injection volumes, fewer vials.
Dosing Protocol
- Initiation: 2.5 mg/wk × 4 weeks.
- Titration: +2.5 mg every 4 weeks.
- Maintenance: 10–15 mg weekly.
- Break between cycles: After completing the cycle, a pause of 4–8 weeks is recommended. Tirzepatide has a half-life of ~5 days — sufficient clearance time is required before a new cycle.
Washout & Cycle Restart
When can I restart?
After completing the cycle, a pause of 4–8 weeks is recommended. Tirzepatide has a half-life of ~5 days — sufficient clearance time is required before a new cycle.
Minimum wait period: 4 weeks
Storage Instructions
- Lyophilized: −20 °C.
- Reconstituted: 2–8 °C; use within 28 days.
Important Notes
- Gradual titration to reduce GI side effects.
Potential Benefits & Side Effects
Potential Benefits:
- Reductions in HbA1c and significant weight loss.
- Fewer vials required for long-term use.
- Smaller injection volumes.
Potential Side Effects:
- GI: Nausea, diarrhea — typically mild.
- Mild injection site reactions.
⚠️ Serious Warnings & Long-Term Risks
The following warnings are based on published literature, FDA labels, and post-marketing surveillance. They do not constitute medical advice. Consult a healthcare professional.
Thyroid C-cell tumors (medullary thyroid carcinoma)
Same warning as GLP-1 RAs. C-cell tumors in rodents. Contraindicated in MTC/MEN 2.
📄 FDA Boxed Warning — Mounjaro® LabelAcute pancreatitis
Risk of acute pancreatitis. Reported in post-marketing surveillance.
📄 FDA Label — Mounjaro®References
- NEJM (2022) — Tirzepatide for obesity
View Source - Mounjaro (Tirzepatide) FDA Prescribing Information (2022) — Mounjaro prescribing information
View Source
Recommended Supplements
Vitamin B12 (Methylcobalamin)
Vitamin D3 + K2
Omega-3 Fish Oil (EPA/DHA)
Protein / Collagen
Fiber Supplement (Psyllium)
External Sources & Regulatory Status
Regulatory Approvals
Mounjaro® / Zepbound® · Type 2 diabetes / Obesity (2022)
Mounjaro® · Type 2 diabetes (2022)
Mounjaro® · Type 2 diabetes (2023)
Mounjaro® · Type 2 diabetes (2024)
Mounjaro® · Type 2 diabetes / Obesity (2023)
Mounjaro® · Type 2 diabetes (2023)
Approved worldwide (6+ countries)
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
Continue Your Research
Explore tools and guides related to this protocol.
Important Disclaimer
The content of this website is provided exclusively for informational and educational purposes within the context of research literature.
Read the full Disclaimer →